

REMARKS

This amendment is being filed in response to the Office Action mailed on April 4, 2007. By this amendment, the first paragraph of the application has been replaced; claim 1 has been amended; and claims 2-4 have been canceled. Reconsideration of this application is respectfully requested in view of the above amendments and further in view of the following remarks.

The specification was objected to as being incomplete. The first paragraph was replaced as suggested by the Examiner.

Next, claims 1-17 were rejected under 35 U.S.C. §112, second paragraph. The use of various terms in claim 1, and claims 2-4 in general, were said to be unclear. Claim 1 was amended as suggested by the Examiner, and claims 2-4 were canceled. Accordingly, Applicants believe this rejection has been obviated.

Finally, claims 1-17 were rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 6,669,981. Applicants submit a terminal disclaimer herewith. Accordingly, Applicants believe that this rejection has been obviated as well.

In view of the foregoing, reconsideration of this application and allowance thereof with claims 1 and 5-17 are respectfully requested.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
100 Headquarters Park Drive  
Skillman, NJ 08558

Date: July 3, 2007

/John M. Kilcoyne/  
John M. Kilcoyne  
Attorney for Applicants  
Reg. No. 33,100  
(908) 904-2372